Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 12/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | VEGFA | P15692 | 2/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.31 |
| ▸ | KLK7 | P49862 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6570197 | 0.78 | HTR6 (0.40) | HTR6RAPGEF4MEN1KMT2A | |
| SCHEMBL4619258 | 0.71 | — | — | |
| SCHEMBL4619254 | 0.71 | — | — | |
| SCHEMBL15973760 | 0.65 | JAK2 (0.41) | — | |
| SCHEMBL6570200 | 0.63 | HTR6 (0.46) | HTR6ALKRAPGEF4VEGFAEGLN1 | |
| SCHEMBL16893175 | 0.62 | RAPGEF4 (0.31) | RAPGEF4 | |
| SCHEMBL537494 | 0.62 | KMT2A (0.38) | RAPGEF4MEN1KMT2A | |
| SCHEMBL909187 | 0.62 | KMT2A (0.38) | RAPGEF4MEN1KMT2A | |
| SCHEMBL909752 | 0.62 | KMT2A (0.38) | RAPGEF4MEN1KMT2A | |
| SCHEMBL5725028 | 0.61 | ALDH1A1 (0.33) | RAPGEF4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6716998-B2 | SUCH AS (2R)-3,4-DIHYDRO-2H-CHROMEN-2-YL-METHYL-4-METHYL-BENZENESULFONATE; METATHESIS RING CLOSING POLYMERIZATION | WYETH | 2004-04-06 | — | — | US | disclosed |
| US-20030100774-A1 | Process for synthesis of 2-yl chroman derivatives | WYETH (US) | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100774-A1 | Process for synthesis of 2-yl chroman derivatives | CDYL, CDY1; CDY1B, CDYL2 | HTR6 744/4885ALK 2792/4885RAPGEF4 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.